Takeda Pharmaceutical (TAK) Short-Term Debt issuances (2017 - 2025)

Takeda Pharmaceutical's Short-Term Debt issuances history runs 7 years deep, the most recent figure standing at $2.3 billion for Q1 2025.

• On a quarterly basis, Short-Term Debt issuances changed N/A year-over-year to $2.3 billion in Q1 2025; TTM through Mar 2025 was $137.6 million, a N/A change from a year earlier, with the FY2026 full-year figure at -$2.3 billion, down 1358.13% from the prior year.
• Short-Term Debt issuances grew to $2.3 billion in Q1 2025 per TAK's latest filing, from -$2.0 billion in the prior quarter.
• Across five years, Short-Term Debt issuances topped out at $2.3 billion in Q1 2025 and bottomed at -$2.0 billion in Q3 2024.
• The 4-year median for Short-Term Debt issuances is $401.3 million (2021), against an average of $348.4 million.
• Across the five-year window, Short-Term Debt issuances jumped 100.01% in 2021 and plunged 113.61% in 2024, its largest moves.
• Year by year, Short-Term Debt issuances stood at $9135.0 in 2021, then jumped by 12589798.96% to $1.2 billion in 2023, then plunged by 274.88% to -$2.0 billion in 2024, then jumped by 212.27% to $2.3 billion in 2025.
• Per Business Quant, the three latest TAK Short-Term Debt issuances figures stand at $2.3 billion (Q1 2025), -$2.0 billion (Q3 2024), and -$109.2 million (Q2 2024).